The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs recommends buying alcon and medacta in swiss medtech sector
UBS recommends buying Swiss medtech stocks Alcon and Medacta, citing their growth potential despite short-term concerns for Alcon's 2025 forecasts. Alcon is expected to launch new products, while Medacta shows sustained growth in orthopaedics. Conversely, Straumann is rated sell due to high expectations and recent strong performance.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.